Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks. Here at the Fool, we use our "This Just In" column to examine some of these picks -- and the track records of the firms behind them -- so individuals can make better investing decisions.
In addition to following professional banks and brokerage houses, anyone can use Motley Fool CAPS to monitor the collective opinions of more than 110,000 members, many of whom demonstrate better investing insight than published analysts do.
Enough top-performing CAPS members have turned bullish on Onyx Pharmaceuticals
Onyx’s one and only drug, Nexavar, was originally approved by the FDA in 2005 for treating kidney cancer. Sales of Nexavar are being challenged by competition from Pfizer's
In the hopes of reaching consistent profitability, Onyx is currently conducting trials for a possible combination of Nexavar with Eli Lilly's
To see what the very best CAPS members are saying now about Onyx -- as well as other winning stocks they are picking -- head on over to CAPS and have a look. The community research and resources in CAPS are totally free, unlike analyst opinions reserved for paying clients.
Always looking ahead, the Motley Fool Rule Breakers service has singled out and recommended several promising drugmakers. To see what rule-breaking stocks David Gardner is picking today, take a free 30-day trial.
Fool contributor Dave Mock upgrades his wardrobe at a less than desirable pace. He owns shares of Pfizer and is the author of The Qualcomm Equation. Pfizer and Eli Lilly are Income Investor picks. Pfizer is an Inside Value recommendation. The Fool's disclosure policy always looks good in a suit.